| Literature DB >> 30968002 |
Tze-Fun Lee1,2, Min Lu1,2, Matteo P Pasquin2,3, Georg M Schmölzer1,2, Po-Yin Cheung1,2,4.
Abstract
Background: Asphyxiated neonates often have myocardial dysfunction and renal insufficiency. Previously we demonstrated that doxycycline improved cardio-renal function through matrix metalloproteinase (MMP)-2 inhibition in an acute swine model of neonatal hypoxia-reoxygenation. The prolonged cardio-renal protective effects of doxycycline in neonates still remained unknown. We therefore hypothesized that the protective effects of doxycycline persisted in surviving subjects.Entities:
Keywords: MMP; asphyxia; doxycycline; newborn; renal failure
Year: 2019 PMID: 30968002 PMCID: PMC6439344 DOI: 10.3389/fped.2019.00075
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Changes in arterial blood gases during hypoxia and recovery.
| Sham-operated | 7.50 ± 0.03 | 7.44 ± 0.05 | 7.45 ± 0.04 | 7.42 ± 0.03 | 7.41 ± 0.01 | 7.40 ± 0.02 | 7.39 ± 0.02 |
| Saline-control | 7.44 ± 0.02 | 7.04 ± 0.05 | 7.48 ± 0.03 | 7.46 ± 0.05 | 7.39 ± 0.02 | 7.37 ± 0.02 | 7.38 ± 0.02 |
| DOX | 7.43 ± 0.02 | 7.07 ± 0.05 | 7.48 ± 0.02 | 7.50 ± 0.03 | 7.38 ± 0.02 | 7.37 ± 0.02 | 7.42 ± 0.02 |
| Sham-operated | 66 ± 6 | 68 ± 6 | 59 ± 6 | 70 ± 4 | 63 ± 5 | 72 ± 3 | 80 ± 10 |
| Saline-control | 62 ± 2 | 20 ± 3 | 61 ± 2 | 62 ± 2 | 67 ± 3 | 68 ± 4 | 67 ± 2 |
| DOX | 61 ± 6 | 21 ± 2 | 55 ± 8 | 57 ± 7 | 60 ± 8 | 69 ± 3 | 75 ± 5 |
| Sham-operated | 33 ± 2 | 35 ± 2 | 38 ± 2 | 34 ± 1 | 32 ± 1 | 31 ± 1 | 37 ± 4 |
| Saline-control | 39 ± 3 | 46 ± 4 | 33 ± 2 | 33 ± 2 | 32 ± 2 | 32 ± 1 | 35 ± 1 |
| DOX | 39 ± 2 | 44 ± 3 | 34 ± 2 | 31 ± 1 | 32 ± 2 | 32 ± 2 | 35 ± 2 |
| Sham-operated | 25.6 ± 1.6 | 27.8 ± 1.3 | 26.0 ± 1.0 | 22.0 ± 1.5 | 20.6 ± 0.5 | 18.9 ± 1.1 | 21.3 ± 1.3 |
| Saline-control | 28.1 ± 0.9 | 12.7 ± 1.3 | 25.0 ± 1.8 | 23.6 ± 1.6 | 18.9 ± 0.5 | 18.6 ± 0.9 | 21.2 ± 0.5 |
| DOX | 26.7 ± 0.9 | 13.6 ± 1.2 | 25.8 ± 0.8 | 24.4 ± 0.9 | 20.2 ± 0.9 | 18.9 ± 1.8 | 22.5 ± 1.1 |
| Sham-operated | 2.73 ± 0.5 | 1.53 ± 0.2 | 1.10 ± 0.16 | 2.47 ± 0.3 | 1.09 ± 0.3 | 1.58 ± 0.7 | 1.08 ± 0.2 |
| Saline-control | 2.24 ± 0.2 | 14.0 ± 1.0 | 2.17 ± 0.84 | 3.24 ± 1.5 | 1.50 ± 0.5 | 1.13 ± 0.3 | 1.05 ± 0.3 |
| DOX | 2.43 ± 0.2 | 13.4 ± 0.8 | 1.83 ± 0.25 | 1.82 ± 0.3 | 0.96 ± 0.2 | 1.13 ± 0.2 | 0.59 ± 0.1 |
p < 0.05 vs. normoxic baseline;
p < 0.05 vs. saline-controls at concurrent time point (2-way repeated measures ANOVA).
Figure 2Daily (A) and total urine output (B) for sham-operated, saline-control and DOX groups after recovery. All values represent mean ± SEM. *p < 0.05 vs. saline-controls at current time point (two-way repeated measures ANOVA or one-way ANOVA).
Temporal changes in heart rate, mean arterial pressure (MAP) and rate-pressure-product (RPP) during hypoxia and recovery.
| Sham-operated | 162 ± 8 | 163 ± 7 | 188 ± 6 | 192 ± 12 | 192 ± 4 | 209 ± 13 | 218 ± 13 |
| Saline-control | 175 ± 8 | 239 ± 26 | 200 ± 13 | 214 ± 9 | 217 ± 14† | 225 ± 16 | 201 ± 6 |
| DOX | 172 ± 7 | 236 ± 15 | 201 ± 11 | 207 ± 8 | 199 ± 7 | 226 ± 6 | 208 ± 10† |
| Sham-operated | 60 ± 6 | 56 ± 4 | 51 ± 4 | 59 ± 7 | 58 ± 5 | 66 ± 7 | 63 ± 4 |
| Saline-control | 63 ± 2 | 71 ± 7 | 53 ± 3 | 54 ± 2 | 57 ± 2 | 66 ± 4 | 57 ± 3 |
| DOX | 67 ± 4 | 60 ± 7 | 56 ± 2 | 48 ± 2 | 50 ± 2 | 57 ± 3 | 62 ± 2 |
| Sham-operated | 9,559 ± 742 | 9,131 ± 597 | 9,644 ± 708 | 11,061 ± 2872 | 11,511 ± 995 | 15,021 ± 2,194 | 14,157 ± 1,757 |
| Saline-control | 10,962 ± 496 | 17783 ± 1,485 | 10,210 ± 785 | 11,647 ± 707 | 12,341 ± 850 | 14,964 ± 1816 | 11,552 ± 726 |
| DOX | 11,242 ± 987 | 16,221 ± 1,843 | 11,417 ± 884 | 9,945 ± 643 | 9,972 ± 687 | 12,838 ± 810 | 12,917 ± 899 |
p < 0.05 vs. normoxic baseline;
p < 0.05 vs. saline-controls at concurrent time point (2-way repeated measures ANOVA).
Left ventricular functions assessed by Millar® catheter in anesthetized newborn piglets after 4 days recovery.
| Heart rate (bpm) | 219 ± 2 | 192 ± 13 | 215 ± 10 | 0.19 |
| Cardiac output (mL/kg/min) | 211 ± 17 | 187 ± 21 | 226 ± 36 | 0.55 |
| Developed pressure (mmHg) | 76 ± 1 | 96 ± 10 | 89 ± 6 | 0.19 |
| dp/dt max (mmHg) | 3,341 ± 446 | 3,481 ± 377 | 3,790 ± 343 | 0.73 |
| dp/dt min (mmHg) | −4,158 ± 233 | −5717 ± 728 | −4,313 ± 629 | 0.17 |
| Tau (ms) | 17 ± 2 | 15 ± 1 | 14 ± 1 | 0.42 |
Changes in various renal biomarkers during recovery.
| Day 1 | 27 ± 9 | 33 ± 7 | 36 ± 7 |
| Day 2 | 15 ± 3 | 17 ± 6 | 30 ± 5 |
| Day 3 | 52 ± 7 | 25 ± 5 | 51 ± 5 |
| Day 4 | 61 ± 15 | 26 ± 5 | 63 ± 7 |
| Total | 154 ± 21 | 101 ± 11 | 181 ± 17 |
| Day 1 | 1.87 ± 0.31 | 2.18 ± 0.59 | 1.78 ± 0.47 |
| Day 2 | 1.65 ± 0.19 | 2.33 ± 0.34 | 1.45 ± 0.23 |
| Day 3 | 1.71 ± 0.26 | 1.88 ± 0.38 | 1.65 ± 0.21 |
| Day 4 | 1.57 ± 0.41 | 1.94 ± 0.16 | 1.82 ± 0.24 |
| Day 1 | 1.96 ± 0.38 | 3.13 ± 0.43 | 2.56 ± 0.34 |
| Day 2 | 1.74 ± 0.28 | 2.88 ± 0.43 | 2.20 ± 0.26 |
| Day 3 | 1.93 ± 0.27 | 3.00 ± 0.36 | 2.05 ± 0.10 |
| Day 4 | 1.94 ± 0.36 | 2.69 ± 0.26 | 2.18 ± 0.34 |
| 0.97 ± 0.04 | 1.32 ± 0.11 | 1.06 ± 0.05 | |
| 0.17 ± 0.01 | 0.24 ± 0.04 | 0.19 ± 0.02 | |
p < 0.05 vs. saline-control group (two-ways repeated measures or one-way ANOVA).
Figure 3Temporal changes in (A) plasma creatinine level and (B) urine NAG/Cr ratio after hypoxia and during recovery of sham-operated, saline-control and DOX groups. All values represent mean ± SEM. *p < 0.05 vs. saline-controls at current time point (two-way repeated measures ANOVA).
Figure 4Correlation between total urine output and (A) plasma creatinine level, (B) total MMP-2 activity, and (C) urine NAG/Cr ratio (Pearson Product Moment test).
Figure 5Representative zymographs of MMP-2 activity in renal tissues of hypoxic piglets after 4 days of reoxygenation, which either received saline (saline-control) or DOX. Sham-operated piglets had no hypoxia and reoxygenation. All values represent mean ± SEM. *p < 0.05 vs. saline-controls (one-way ANOVA).
Figure 6Correlation between total MMP-2 activity and (A) plasma creatinine level, and (B) urine NAG /Cr ratio (Pearson Product Moment test).